Media stories about AstraZeneca (LON:AZN) have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of -2.78 on their scale. InfoTrie also gave news stories about the biopharmaceutical company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted AstraZeneca’s ranking:
- AstraZeneca Q3 2019 Earnings Preview – Seeking Alpha (seekingalpha.com)
- AstraZeneca commits $35M to reduce NCDs – BSA bureau (biospectrumasia.com)
- AstraZeneca’s (AZN) Buy Rating Reiterated at Shore Capital (americanbankingnews.com)
- AstraZeneca (LON:AZN) Getting Critical News Coverage, InfoTrie Reports (americanbankingnews.com)
- 3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix – Benzinga (benzinga.com)
A number of research firms have recently weighed in on AZN. Goldman Sachs Group set a GBX 5,500 ($71.87) price objective on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, October 1st. UBS Group reiterated a “sell” rating on shares of AstraZeneca in a research note on Monday, September 30th. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday, September 20th. Bryan, Garnier & Co reiterated a “neutral” rating on shares of AstraZeneca in a research note on Wednesday, July 3rd. Finally, JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of GBX 7,137.81 ($93.27).
AZN stock opened at GBX 6,919 ($90.41) on Thursday. The firm has a market cap of $90.35 billion and a PE ratio of 40.41. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95. The firm’s fifty day moving average is GBX 7,059.07 and its 200 day moving average is GBX 6,536.76. AstraZeneca has a one year low of GBX 5,312 ($69.41) and a one year high of GBX 8,227.88 ($107.51).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Purposes and Functions of the Federal Reserve
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.